From isoniazid to psychobiotics: the gut microbiome as a new antidepressant target

Show simple item record Butler, Mary I. Sandhu, Kiran V. Cryan, John F. Dinan, Timothy G. 2019-04-29T09:33:50Z 2019-04-29T09:33:50Z 2019-03-12
dc.identifier.citation Butler, M. I., Sandhu, K., Cryan, J. F., Dinan, T. G. (2019) 'From isoniazid to psychobiotics: the gut microbiome as a new antidepressant target', British Journal of Hospital Medicine, 80 (3), pp. 139-145. doi: 10.12968/hmed.2019.80.3.139 en
dc.identifier.volume 80 en
dc.identifier.issued 3 en
dc.identifier.startpage 139 en
dc.identifier.endpage 145 en
dc.identifier.issn 1750-8460
dc.identifier.doi 10.12968/hmed.2019.80.3.139 en
dc.description.abstract An awareness of the importance of the gut–brain axis in psychiatric disorders such as depression is increasing. The gut microbiome is a key component of this axis. Gut bacteria can communicate with the brain through a variety of pathways including the hypothalamic–pituitary–adrenal axis, immune modulation, tryptophan metabolism and the production of various neuroactive compounds. Patients with depression, and other mood and anxiety disorders, show distinct compositional changes in their gut bacteria profile, raising the question about a possible aetiological role for the microbiome in these disorders. Evidence is emerging that the gut microbiome may represent a new potential antidepressant target and the term ‘psychobiotic’ has been coined to describe bacteria which confer mental health benefits. Gut bacteria are easily accessible and can be altered in a variety of ways including through the use of probiotics, prebiotics and dietary change. Psychobiotics containing various Lactobacillus and Bifidobacterium species have demonstrated the ability to improve mood, reduce anxiety and enhance cognitive function in both healthy populations and patient groups. This article provides an overview of the identification and development of antidepressant psychobiotics, from the preclinical evidence in the laboratory to the more recent encouraging results from human trials. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Mark Allen Healthcare en
dc.rights © 2019 MA Healthcare Ltd. This document is the Accepted Manuscript version of a Published Work that appeared in final form in British Journal of Hospital Medicine, copyright © MA Healthcare, after peer review and technical editing by the publisher. To access the final edited and published work see en
dc.subject Metagenome en
dc.subject Obesity en
dc.subject Gut microbial en
dc.subject Psychobiotics en
dc.subject Gut bacteria en
dc.subject Gut-brain axis en
dc.title From isoniazid to psychobiotics: the gut microbiome as a new antidepressant target en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Ted Dinan, Psychiatry, University College Cork, Cork, Ireland. +353-21-490-3000 Email: en
dc.internal.availability Full text available en Access to this article is restricted until 6 months after publication by request of the publisher. en 2019-09-12 2019-04-29T09:26:40Z
dc.description.version Accepted Version en
dc.internal.rssid 483353192
dc.description.status Peer reviewed en
dc.identifier.journaltitle British Journal of Hospital Medicine en
dc.internal.copyrightchecked No !!CORA!!
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress en
dc.identifier.eissn 1759-7390

Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement